Results 21 to 30 of about 182,433 (270)

Interferon-induced interstitial lung disease: a rare adverse effect induced by pegylated interferon-alpha in a patient with chronic hepatitis B-case report. [PDF]

BMC Pulm Med
Yu H, Zhang S, Zhou Y, Wen Q, Wang Y, Yang X.   +5 more
europepmc   +2 more sources

Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study. [PDF]

Front Cell Infect Microbiol
Gong H, Liu M, Zhang X, Sun W, Deng H, Liu W, Wu Y, Deng G, Xia J, Mao Q, Jiang L.   +10 more
europepmc   +2 more sources

Effectiveness of pegylated interferon-α combined with antiretroviral therapy on HIV reservoir clearance in acute HIV infection: study protocol for a randomised controlled trial at a tertiary infectious disease hospital in Beijing, China. [PDF]

BMJ Open
Zhu L, Wang F, Ji J, Xiao J, Zhang Y, Huang T, Liu Y, Lu J, Song Q, Cao Y, Dai L, Zhang T.   +11 more
europepmc   +3 more sources

Pegylated Interferon-based Treatment Improves Response Rates in Immune-tolerant Patients with Chronic Hepatitis B: A Prospective Trial. [PDF]

J Clin Transl Hepatol
Liu M, Zuo L, Zhang Y, Bu B, Xiao A, Zhu L, Ma X, Wang Y, Yue W, Geng J, Xia X.   +10 more
europepmc   +3 more sources

Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients. [PDF]

Virulence
Li J, Li H, Lin C, Jiang R, Wang L, He Y, Yang X, Gong K, Xun Z, Zheng Q.   +9 more
europepmc   +3 more sources

Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study. [PDF]

JHEP Rep
Schwarz M, Hintersteininger M, Schwarz C, Panzer M, Pfisterer N, Loschko N, Hartl L, Dorn L, Laferl H, Trauner M, Stättermayer AF, Mandorfer M, Graziadei I, Maieron A, Moschen A, Aigner E, Stadlbauer V, Madl C, Aberle SW, Zoller H, Gschwantler M, Reiberger T, Jachs M.   +22 more
europepmc   +3 more sources

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C [PDF]

International Journal of Circumpolar Health, 2016
Background: There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations. Objective: To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI ...
Stephen E. Livingston, Lisa J. Townshend-Bulson, Dana J. T. Bruden, Chriss E. Homan, James E. Gove, Julia N. Plotnik, Brenna C. Simons, Philip R. Spradling, Brian J. McMahon   +8 more
doaj   +1 more source

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis. [PDF]

Cancers (Basel)
Machherndl-Spandl S, Kiehberger M, Sygulla V, Kaynak E, Zach O, Webersinke G, Gruber-Rossipal C, Beham-Schmid C, Maier E, Strassl I, Clausen J, Nikoloudis A, Schimetta W, Rumpold H, Buxhofer-Ausch V.   +14 more
europepmc   +3 more sources

Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b. [PDF]

Front Pharmacol
Ji C, Ji X, Li H, Wang Q.
europepmc   +3 more sources

Importance of adherence for efficacy of hepatitis C combined therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Dual antiviral therapy with pegylated interferon alfa-2a and ribavirin leads do sustained elimination of hepatitis C virus infection in over 50% patients with genotypes 1 and 4 and in over 80% with genotypes 2 and 3.
Nožić Darko, Delić Dragan, Božić Milena, Fabri Milotka, Svorcan Petar, Konstantinović Ljiljana   +5 more
doaj   +1 more source